TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3513564
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of inhaled and oral metaproterenol
Study: 12854895
Drug: CHOP-HC (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-HC (high dose cyclophosphamide consolidation)
Study: 10536557
Drug: rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.9 mg kg‐1
Study: 10536557
Drug: succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1.5 mg kg‐1
Study: 30999196
Drug: TXA single
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA single dose
Study: 30999196
Drug: TXA two
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA two doses
Study: 24346155
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin 12 hours and 40 mg atorvastatin 2 hours before PCI
Study: 24346155
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin preoperatively for 7 days
Study: 21685819
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 25 mL of plain water before and every 5 min (DR)
Study: 21685819
Drug: Mouth rinse
Normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinse with 25 mL of plain water before and every 5 min (MR)
Study: 17241841
Drug: Contraceptive counseling
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive counseling with optional advance EC prescription
Study: 12625668
Drug: Methyldopa 750‐4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa 750‐4000 mg/day (n=34)
Study: 12625668
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=36)
Study: 1959195
Drug: Nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 5 mg twice daily
Study: 8829020
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 40 mg sustained-release
Study: 30982761
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily for 5 days preoperatively, the morning of surgery, and the first postoperative day
Study: 30982761
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 5 days preoperatively, the morning of surgery, and the first postoperative day
Study: 17522559
Drug: Intramuscular aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular aripiprazole
Study: 20055763
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg/ml
Study: 18726957
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml lidocaine (group L)
Study: 18726957
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml lidocaine + 0.5 mg dinitrate isosorbide (group LN)
Study: 15735447
Drug: Baseline pVL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline pVL >100,000 copies/mL
Study: 27471314
Drug: Clonidine 1 µg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 µg·kg(‐1)
Study: 27471314
Drug: Clonidine 1 µg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 µg·kg(‐1) and ketamine 1 mg·kg(‐1)
Study: 22266895
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral clarithromycin twice daily for 5 months
Study: 18039954
Drug: Valganciclovir 450
Normalized name: valganciclovir 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir 450 mg orally twice daily
Study: 18039954
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg orally daily
Study: 12126385
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of hydrocodone/1000 mg of acetaminophen
Study: 7741785
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Analgin) containing 1 g of metamizole
Study: 7741785
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation containing 1 g of metamizole
Study: 7741785
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Analgin)
Study: 1904450
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single dose of melatonin
Study: 1904450
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg melatonin in three divided doses (1 mg at 0800 hrs., 0.75 mg at 1000 and 1200 hrs.)
Study: 30446762
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid (IFA) (FA, Fe 30 mg)
Study: 30446762
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid alone (FA) (400 μg)
Study: 22516321
Drug: MS Invigor8
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS Invigor8 (Internet-based cognitive behavioural therapy self-management programme)
Study: 14525749
Drug: Any analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any analgesics accepted
Study: 14525749
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic need
Study: 14525749
Drug: Parenteral analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral analgesics accepted
Study: 6337982
Drug: Inhaled atropine
Normalized name: atropine sulfate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled atropine (0.5 mg)
Study: 6337982
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine (0.5 mg)
Study: 6337982
Drug: Inhaled and
Normalized name: Umeclidinium and Vilanterol Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled and intravenous placebos
Study: 31507054
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (specific dosage and duration not mentioned)
Study: 31507054
Drug: Intermittent statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent statin dosing, new LDL-lowering drugs, LDL apheresis, and supplements (specific details not mentioned)
Study: 28118323
Drug: Chemotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (weekly paclitaxel 80 mg/m² or four weekly pegylated liposomal doxorubicin 40 mg/m²)
Study: 3051880
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg daily)
Study: 19447919
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg/d
Study: 16527576
Drug: BCG (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (six weekly instillations of 80 mg BCG [Tokyo 172 strain])
Study: 16527576
Drug: Doxorubicin (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (17 instillations of 20 mg doxorubicin)
Study: 7790757
Drug: trapidil 200
Normalized name: trapidil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trapidil 200 mg tablets bid
Study: 2899451
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion at a dose rate of 80 +/- 59 micrograms/kg/min
Study: 26588810
Drug: Closed-loop (CL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop (CL) therapy with subcutaneous insulin via CL pump (n = 7)
Study: 26588810
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections with blinded continuous glucose monitor (CGM) (n = 7)
Study: 19006503
Drug: Theophylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300 mg daily)
Study: 17213007
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg (older group)
Study: 8442620
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg orally once daily or 200 mg intravenously every 12 hours)
Study: 3620399
Drug: No oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No oxytocin infusion (control)
Study: 31909811
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) - 20 g daily during pregnancy and 6 months postpartum; infants received LNS from 6 to 18 months.
Study: 31909811
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients (MMN) - 1 capsule daily during pregnancy and 6 months postpartum; combined with IFA group for analysis.
Study: 31909811
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA) - 1 capsule daily during pregnancy, then placebo postpartum; combined with MMN group for analysis.
Study: 12363007
Drug: Overall antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antimicrobial use among children <7 years old (from 13.6 to 11.1 defined daily dosages/1000 children per day)
Study: 1704561
Drug: Steroid-tipped leads
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-tipped leads
Study: 24383602
Drug: Levobupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine plus 1 μg·kg(‐1) dexmedetomidine
Study: 24383602
Drug: Levobupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine plus 2 μg·kg(‐1) dexmedetomidine
Study: 19309747
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg modafinil once daily for 4 weeks (Phase 1)
Study: 16750463
Drug: Sumatriptan 4
Normalized name: sumatriptan 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 4 mg SC
Study: 10206720
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACh and VIP
Study: 10206720
Drug: Cetirizine (H1-antagonist)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine (H1-antagonist) pretreatment before ACh injection
Study: 2360502
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 to 800 mg once daily)
Study: 26044228
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and water capsule-guided local injection of botulinum toxin type A (group B)
Study: 26044228
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug treatment (group A)
Study: 23108953
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 (10 mg/kg QW) plus cisplatin/capecitabine (CX)
Study: 23108953
Drug: AMG 386
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 (3 mg/kg QW) plus cisplatin/capecitabine (CX)
Study: 18672290
Drug: Nilvadipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (2 mg twice daily)
Study: 17039647
Drug: dexamethasone suspension
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone suspension
Study: 17039647
Drug: prednisone suspension
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone suspension
Study: 17039647
Drug: cherry‐flavored prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: cherry‐flavored prednisolone suspensions
Study: 12694213
Drug: Carriers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carriers of TNFA-308*1/2 (*G/A) genotype
Study: 9005589
Drug: Mitomycin-C 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C 30 mg for 12 months
Study: 9005589
Drug: Mitomycin-C 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C 40 mg for 6 months
Study: 25540035
Drug: Cognitive-behavioral couple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral couple therapy
Study: 18794543
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and Estramustine (D/E); 280 mg orally three times a day on days 1 to 5 and 8 to 12, every 3 weeks, plus prednisone (10 mg/d)
Study: 18794543
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (D); 35 mg/m(2) on days 2 and 9, every 3 weeks, plus prednisone (10 mg/d)
Study: 10329815
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 400 micrograms (low dose) after placebo
Study: 10329815
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 1600 micrograms (high dose) after placebo
Study: 10329815
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 400 micrograms (low dose) after formoterol 12 micrograms
Study: 10329815
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 1600 micrograms (high dose) after formoterol 12 micrograms
Study: 10329815
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 400 micrograms (low dose) after salmeterol 50 micrograms
Study: 10329815
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 1600 micrograms (high dose) after salmeterol 50 micrograms
Study: 7757335
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin therapy for 12 months
Study: 2185303
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg/d
Study: 2185303
Drug: Milnacipran 50
Normalized name: milnacipran 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 50 mg/d
Study: 7033745
Drug: Active pharmacological
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pharmacological treatment
Study: 31805992
Drug: Calprotectin levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calprotectin levels at DMARD tapering/stopping
Study: 26455521
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily rosuvastatin
Study: 23401474
Drug: Silexan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan (160 mg)
Study: 21617837
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly health information)
Study: 20396722
Drug: Artrofoon in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artrofoon in combination with SCENAR therapy
Study: 20396722
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in combination with SCENAR therapy
Study: 17519319
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml water
Study: 2900819
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (E) loading dose of 500 micrograms/kg/min for 1 min
Study: 2900819
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (E) loading dose of 500 micrograms/kg/min for 2 min
Study: 2900819
Drug: Esmolol (E)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (E) loading dose of 500 micrograms/kg/min for 4 min
Study: 29641212
Drug: Hippotherapy (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (24 sessions, twice weekly)
Study: 27543447
Drug: Amiselimod 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod 0.1 mg
Study: 27543447
Drug: Amiselimod 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod 0.2 mg
Study: 18762864
Drug: Kefir (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir (oral lavage and 250 ml swallowed)
Study: 18762864
Drug: 0.09% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% NaCl (oral lavage twice a day)
Study: 15189747
Drug: LP +
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP + N (Insulin lispro + NPH)
Study: 3356051
Drug: Acetaminophen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (20 mg.kg‐1 administered rectally)
Study: 3356051
Drug: Meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1 mg.kg‐1 administered intramuscularly)
Study: 22206271
Drug: High-energy and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy and high-protein diet (group B, n = 12, 4.2 g/kg/d protein and 150 kcal/kg/d)
Study: 22206271
Drug: High-energy and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy and high-protein diet (group C, n = 12, 4.7 g/kg/d protein and 150 kcal/kg/d)
Study: 22206271
Drug: Standard preterm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preterm formula (group A, n = 8, 3.7 g/kg/d protein and 129 kcal/kg/d)
Study: 356247
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg b.i.d.
Study: 12072586
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lercanidipine
Study: 12072586
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lercanidipine
Study: 10436254
Drug: Low-dose glyburide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glyburide plus metformin (5, 7.5 or 10 mg/day glyburide and 800, 1,200 or 1,600 mg/day metformin)
Study: 10436254
Drug: High-dose glyburide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glyburide alone (5, 10 or 15 mg/day)
Study: 10436254
Drug: Low-dose glyburide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glyburide plus metformin
Study: 8000659
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotetan preoperatively
Study: 8000659
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin preoperatively
Study: 8000659
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin preoperatively followed by three postoperative doses
Study: 27017895
Drug: Citrulline-malate (CM)
Normalized name: citrulline malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline-malate (CM) supplementation (12 g dextrose + 8 g CM)
Study: 27017895
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) (12 g dextrose)
Study: 23666589
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg IORA vancomycin
Study: 23666589
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg IORA vancomycin
Study: 23666589
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g systemic vancomycin
Study: 23563461
Drug: 0.75% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% hyperbaric ropivacaine + 25 μg (0.5 ml) fentanyl
Study: 23563461
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg (l ml) hyperbaric bupivacaine + 25 μg (0.5 ml) fentanyl
Study: 16639341
Drug: ESO 20
Normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO 20 mg qd + FPV 1400 mg bid
Study: 16639341
Drug: ESO 20
Normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO 20 mg qd + FPV 700 mg bid + RTV 100 mg bid
Study: 16639341
Drug: FPV 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 1400 mg bid
Study: 16639341
Drug: FPV 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 700 mg bid + RTV 100 mg bid
Study: 12762259
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment during the first hour
Study: 12762259
Drug: Thrombolytics (third-generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytics (third-generation agents like reteplase and tenecteplase)
Study: 1809524
Drug: 0.4% Sn2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% Sn2 gel used while toothbrushing every day for three months
Study: 1809524
Drug: 1.1% neutral
Normalized name: Neutragard 1.1% Neutral Sodium Fluoride Gel (Mint)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% neutral NaF gel for three months followed by twice daily rinsing with a remineralizing mouthrinse
Study: 28643477
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine polyphenols (RWPs) 600 mg/d
Study: 26365326
Drug: CEE alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE alone (0.625 mg/d)
Study: 26365326
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA (0.625 mg/d CEE and 2.5 mg/d MPA)
Study: 20565840
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with cervical carcinoma (CC)
Study: 19124372
Drug: Nebulized formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized formoterol fumarate (20 microg) inhalation solution for nebulization (FFIS)
Study: 19124372
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate dry powder inhalation (12 microg) (FA)
Study: 15679563
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (n = 216)
Study: 10556133
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 microg twice a day) for 4 weeks